Table 2. Summary of E-Flux predicted mycolic acid enhancers from Boshoff data set.

Predicted Enhancers
Chlorpromazine/GSNO	Non-specific	Weak*	New
Rifapentine‡	Non-specific	Weak	New
Rifampicin‡	Non-specific	Weak	New
Chlofazimine/GSNO	Non-specific	Weak	New
GSNO	Specific	Strong*	New
Menadione/GSNO	Non-specific	Very weak*	New
Triclosan	Non-specific	Very weak*	Incorrect?

Results are shown for all significant predictions from the set of 437 experiments in Boshoff et al [17]. Strong effects are defined as effects showing greater than +/−3 log change between control and drug; weak enhancing effects have greater than +1 log change, and we list two very weak effects defined as prediction lying outside the 95% null confidence interval. Specific effects indicate effects on mycolic acid biosynthesis as contrasted to effects over a broad range of pathways – see text for more details.

^*Prediction made only for certain replicates.

^‡Prediction made only for certain doses.

Conditions with both enhancing and inhibiting predictions among replicates were excluded.